• Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

Despite the initial intent of charitable foundations to be not-for-profit, some of them tend to morph into organizations with bigger aspirations.

Up to 1 billion people in the world suffer from neurological disorders. Currently, many brain scans are still evaluated by visual inspection. Quantification of different biomarkers in these brain scans can improve diagnosis, patient monitoring and, eventually, patient outcome. The Leuven-based company Icometrix provides software to bring quantification of brain scans into clinical trials and clinical practice. We should stop eye-balling images of brain scans and step into the world of quantitative analysis.

It has long been known that exposure to microbes can play a protective role against the subsequent development of asthma. Researchers from GIGA of the University of Liège provide an explanation and propose to use this discovery to set up a strategy of cell therapy to treat asthma in humans. Their discovery is published in Immunity.

ARGX-115, an antibody targeting to inhibit the release of TGF-beta from regulatory T-cells in an innovative way, reaches its first preclinical milestone. This triggers a $10 million payment from development partner AbbVie.

  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

Despite the initial intent of charitable foundations to be not-for-profit, some of them tend to morph into organizations with bigger aspirations.

Up to 1 billion people in the world suffer from neurological disorders. Currently, many brain scans are still evaluated by visual inspection. Quantification of different biomarkers in these brain scans can improve diagnosis, patient monitoring and, eventually, patient outcome. The Leuven-based company Icometrix provides software to bring quantification of brain scans into clinical trials and clinical practice. We should stop eye-balling images of brain scans and step into the world of quantitative analysis.

It has long been known that exposure to microbes can play a protective role against the subsequent development of asthma. Researchers from GIGA of the University of Liège provide an explanation and propose to use this discovery to set up a strategy of cell therapy to treat asthma in humans. Their discovery is published in Immunity.

ARGX-115, an antibody targeting to inhibit the release of TGF-beta from regulatory T-cells in an innovative way, reaches its first preclinical milestone. This triggers a $10 million payment from development partner AbbVie.